39702579|t|CAR-T cell therapy for the treatment of adult high-grade gliomas.
39702579|a|Treatment for malignant primary brain tumors, including glioblastoma, remains a significant challenge despite advances in therapy. CAR-T cell immunotherapy represents a promising alternative to conventional treatments. This review discusses the landscape of clinical trials for CAR-T cell therapy targeting brain tumors, highlighting key advancements like novel target antigens and combinatorial strategies designed to address tumor heterogeneity and immunosuppression, with the goal of improving outcomes for patients with these aggressive cancers.
39702579	0	5	CAR-T	CellLine	CVCL:4140
39702579	57	64	gliomas	Disease	MESH:D005910
39702579	90	110	primary brain tumors	Disease	MESH:D001932
39702579	122	134	glioblastoma	Disease	MESH:D005909
39702579	197	202	CAR-T	CellLine	CVCL:4140
39702579	344	349	CAR-T	CellLine	CVCL:4140
39702579	373	385	brain tumors	Disease	MESH:D001932
39702579	493	498	tumor	Disease	MESH:D009369
39702579	576	584	patients	Species	9606
39702579	607	614	cancers	Disease	MESH:D009369

